NRC Health (NRC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
National Research Corporation, doing business as NRC Health, provides AI-enabled subscription-based solutions for healthcare organizations, focusing on patient experience, employee engagement, and reputation management. This report covers the quarterly period ended September 30, 2025. The company operates as a single reporting segment. Effective September 29, 2025, Shane Harrison assumed the role of Chief Financial Officer.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $34.6M | $35.8M | $102.2M | $106.2M |
| Operating Income | $7.7M | $8.0M | $17.9M | $25.6M |
| Net Income | $4.1M | $5.7M | $9.8M | $18.2M |
| Diluted EPS | $0.18 | $0.24 | $0.43 | $0.76 |
| Operating Margin | 22% | 22% | 18% | 24% |
| Effective Tax Rate | 34% | 22% | 33% | 23% |
| Cash from Operations (9M) | $19.3M (vs $28.2M prior year) | |||
| Total Debt (Gross) | $84.4M ($80.4M Term Loan + $4.0M Current) | |||
| Cash & Equivalents | $2.2M | |||
| Working Capital | Deficit of $18.2M |
Material Changes vs. Prior Period
- Revenue Decline: Q3 revenue decreased 3% ($1.2M) and 9M revenue decreased 4% ($4.0M). This was driven by a decrease in recurring revenue from existing clients, partially offset by new client growth.
- Expense Dynamics: Direct expenses decreased significantly (19% in Q3) due to lower conference costs (timing of the annual HUB event) and workforce reductions. However, SG&A expenses increased 12% in Q3 and 21% in 9M, primarily due to new executive compensation arrangements and increased legal/accounting fees.
- Profitability Pressure: Operating income declined 30% on a 9M basis due to the combination of lower revenue and higher SG&A. Net income dropped 46% for the 9M period.
- Debt Structure: In February 2025, the company entered a new credit agreement, refinancing prior debt. This resulted in a $67,000 loss on extinguishment of debt and increased interest expense due to higher borrowings on the Delayed Draw Term Loan.
- Tax Rate Increase: The effective tax rate rose to 34% (Q3) and 33% (9M) from 22% and 23% respectively, largely due to deductible limitations on executive cash bonuses.
Outlook, Risks, and Management Commentary
- Leading Indicator: Total Recurring Contract Value (TRCV) increased 8% to $141.7M as of September 30, 2025, suggesting potential future revenue growth despite current declines.
- Liquidity: Despite a working capital deficit of $18.2M, management asserts sufficient liquidity via $2.2M cash, $30.0M available on the Revolving Loan, and $27.6M available on the Delayed Draw Term Loan.
- Capital Allocation: The company completed its $20M stock repurchase program (2025 Program) in Q3, buying back 618,264 shares. Dividends of $0.12 per share were declared for the quarter.
- Risks: Key risks include client non-renewal, competitive pressure, potential impact of the "One Big Beautiful Bill Act" tax legislation (currently being evaluated), and reliance on a single operating segment.
Investor Verification Checklist
- TRCV vs. Revenue Lag: Verify if the 8% growth in TRCV translates to revenue growth in upcoming quarters, given the current revenue decline.
- Executive Compensation Impact: Assess the long-term impact of new executive compensation structures on SG&A and the effective tax rate.
- Debt Service Capacity: Confirm compliance with financial covenants (Fixed Charge Coverage Ratio > 1.10x; Cash Flow Leverage Ratio < 3.50x) given the increased debt load and interest rates.
- Working Capital Deficit: Monitor the $18.2M working capital deficit and its drivers, specifically the timing of deferred revenue and accrued wages.
- Capital Expenditures: Review the $9.6M in 9M capital expenditures (building renovations and software) to ensure ROI aligns with strategic goals.